New hope for leukemia patients: drug cocktail shows promise
NCT ID NCT06773936
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases of drug combinations. The main goal is to see if more patients achieve a deep molecular remission by day 85.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
asciminib, dasatinib, prednisone, blinatumomab, methotrexate, dexamethasone
What this could lead to
If successful, this could improve remission rates and offer a more effective treatment option for people with newly diagnosed Ph+ acute lymphoblastic leukemia.
What could go wrong
This is an early phase II trial with only 55 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baptist Memorial Health Care
Memphis, Tennessee, 38120, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Northwell Health/Center for Advanced Medicine
Lake Success, New York, 11042, United States
-
UC Irvine Medical Center
Orange, California, 92868, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Cincinnati Cancer Ctr-UC Medical Ctr
Cincinnati, Ohio, 45267, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States